Outlook Therapeutics Inc. signed an exclusive commercial distribution agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland. Mediconsult will have exclusive rights to market, import, distribute and commercialize the product and will handle Swiss regulatory activities, including seeking and maintaining marketing authorization, while Outlook Therapeutics will remain responsible for manufacturing, product supply and related intellectual property. The companies said LYTENAVA is expected to be available in Switzerland in 2027, subject to marketing authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9657626-en) on February 19, 2026, and is solely responsible for the information contained therein.